TriangleOsimertinib (NCT07874490)
Osimertinib trial for Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (NCT07874490). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic lung cancer carrying an EGFR exon-19 deletion or L858R mutation, detectable tumor DNA in blood, and no metastatic chemotherapy. Limited prior osimertinib is allowed.
The idea: test adding cyclosporine for tumor-DNA clearance. Osimertinib blocks mutant EGFR signaling; cyclosporine suppresses immune-cell activity. After three weeks of osimertinib, only patients with persistent tumor DNA are randomized to osimertinib alone or the combination. Both drugs are oral; blood tests repeat every three weeks.
This phase 2 study plans 60 patients. Elaine Shum leads at NYU’s recruiting New York site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.